DSG2 Monoclonal Antibody - EP3464355A1 - Asclepiumm Taiwan
Summary
The European Patent Office published patent application EP3464355A1 for a DSG2 monoclonal antibody and use thereof, filed by Asclepiumm Taiwan Co., Ltd. The application names CHEN Min-Che, CHANG Po-Hao, and LIU Ya-Chuan as inventors. The patent covers immunological compositions classified under IPC C07K 16/28, C12N 15/13, A61K 39/395, and A61P 35/00, with designated states spanning all current EPO member states and extension states.
What changed
The EPO published patent application EP3464355A1 for a DSG2 monoclonal antibody, covering compositions and methods of use in immunological applications. This represents a new patent filing publication in the biotechnology sector.
For companies operating in the pharmaceutical or biotechnology space, this publication signals potential future IP landscape changes. Competitors developing similar antibody technologies should review the claims upon grant to assess freedom-to-operate implications. Research institutions and biotech firms with active pipelines may need to evaluate whether their programs could conflict with the disclosed invention once the patent grants.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DSG2 MONOCLONAL ANTIBODY AND USE THEREOF
Publication EP3464355A1 Kind: A1 Apr 15, 2026
Applicants
Asclepiumm Taiwan Co., Ltd.
Inventors
CHEN, Min-Che, CHANG, Po-Hao, LIU, Ya-Chuan
IPC Classifications
C07K 16/28 20060101AFI20191217BHEP C12N 15/13 20060101ALI20191217BHEP A61K 39/395 20060101ALI20191217BHEP A61P 35/00 20060101ALI20191217BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.